THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Start-up’s drug targets inflammation in diabetics

Xconomy.Com / October 24, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

After Jill Milne and Michael Jirousek left Sirtris Pharmaceuticals Inc. in 2008, they decided to pursue a titillating but largely unproven idea: that fighting inflammation might help control Type 2 diabetes.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.

    waiting for twitterWaiting for Twitter to feed in the latest...